234 related articles for article (PubMed ID: 15652424)
1. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome.
Wirtz PW; Willcox N; van der Slik AR; Lang B; Maddison P; Koeleman BP; Giphart MJ; Wintzen AR; Roep BO; Verschuuren JJ
J Neuroimmunol; 2005 Feb; 159(1-2):230-7. PubMed ID: 15652424
[TBL] [Abstract][Full Text] [Related]
2. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.
Titulaer MJ; Maddison P; Sont JK; Wirtz PW; Hilton-Jones D; Klooster R; Willcox N; Potman M; Sillevis Smitt PA; Kuks JB; Roep BO; Vincent A; van der Maarel SM; van Dijk JG; Lang B; Verschuuren JJ
J Clin Oncol; 2011 Mar; 29(7):902-8. PubMed ID: 21245427
[TBL] [Abstract][Full Text] [Related]
3. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
4. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor.
Wirtz PW; Roep BO; Schreuder GM; van Doorn PA; van Engelen BG; Kuks JB; Twijnstra A; de Visser M; Visser LH; Wokke JH; Wintzen AR; Verschuuren JJ
Hum Immunol; 2001 Aug; 62(8):809-13. PubMed ID: 11476904
[TBL] [Abstract][Full Text] [Related]
5. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.
Lipka AF; Verschuuren JJ; Titulaer MJ
Ann N Y Acad Sci; 2012 Dec; 1275():70-7. PubMed ID: 23278580
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer.
Parsons KT; Kwok WW; Gaur LK; Nepom GT
Hum Immunol; 2000 Aug; 61(8):828-33. PubMed ID: 10980394
[TBL] [Abstract][Full Text] [Related]
7. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
Payne M; Bradbury P; Lang B; Vincent A; Han C; Newsom-Davis J; Talbot D
J Thorac Oncol; 2010 Jan; 5(1):34-8. PubMed ID: 19934775
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel autoantibodies in myasthenic syndrome and small cell lung cancer.
Pelucchi A; Ciceri E; Clementi F; Marazzini L; Foresi A; Sher E
Am Rev Respir Dis; 1993 May; 147(5):1229-32. PubMed ID: 8387255
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.
Wirtz PW; Nijnuis MG; Sotodeh M; Willems LN; Brahim JJ; Putter H; Wintzen AR; Verschuuren JJ;
J Neurol; 2003 Jun; 250(6):698-701. PubMed ID: 12796832
[TBL] [Abstract][Full Text] [Related]
10. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
11. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.
Titulaer MJ; Verschuuren JJ
Ann N Y Acad Sci; 2008; 1132():129-34. PubMed ID: 18567862
[TBL] [Abstract][Full Text] [Related]
12. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.
Wirtz PW; Lang B; Graus F; van den Maagdenberg AM; Saiz A; de Koning Gans PA; Twijnstra A; Verschuuren JJ
J Neuroimmunol; 2005 Jul; 164(1-2):161-5. PubMed ID: 15904978
[TBL] [Abstract][Full Text] [Related]
13. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families.
Wirtz PW; Bradshaw J; Wintzen AR; Verschuuren JJ
J Neurol; 2004 Oct; 251(10):1255-9. PubMed ID: 15503107
[TBL] [Abstract][Full Text] [Related]
14. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer.
Wirtz PW; Wintzen AR; Verschuuren JJ
Muscle Nerve; 2005 Aug; 32(2):226-9. PubMed ID: 15793845
[TBL] [Abstract][Full Text] [Related]
15. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer.
Liu Y; Xi J; Zhou L; Wu H; Yue D; Zhu W; Lin J; Lu J; Zhao C; Qiao K
J Clin Neurosci; 2019 Jul; 65():41-45. PubMed ID: 31072737
[TBL] [Abstract][Full Text] [Related]
17. Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer.
Wang S; Bruzzi J; Rodriguez-Garza VP; Komaki RR
Clin Lung Cancer; 2006 Jan; 7(4):282-4. PubMed ID: 16512985
[TBL] [Abstract][Full Text] [Related]
18. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
Takamori M
J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
[TBL] [Abstract][Full Text] [Related]
20. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Shiraishi H; Motomura M
Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
